By Professor Andrew David Carr

Journal articles

Revell AD; Wang D; Wood R; Morrow C; Tempelman H; Hamers RL; Alvarez-Uria G; Streinu-Cercel A; Ene L; Wensing AMJ; DeWolf F; Nelson M; Montaner JS; Lane HC; Larder BA; RDI study group , 2013, 'Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings.', J Antimicrob Chemother, 68, pp. 1406 - 1414, http://dx.doi.org/10.1093/jac/dkt041

Sasson SC; Oon A; Chagantri J; Brew BJ; Carr A, 2013, 'Posterior reversible encephalopathy syndrome (PRES) in an HIV-1 infected patient with disseminated varicella zoster virus: a case report', BMC Infectious Diseases, 13, pp. 396 - 396, http://dx.doi.org/10.1186/1471-2334-13-396

Jansson J; Wilson D; Carr A; Petoumenos K; Boyd M, 2012, 'Currently available medications may not be sufficient for lifelong treatment of HIV', JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, pp. 4 - 4, http://dx.doi.org/10.7448/IAS.15.6.18077

Lee FJ; Carr A, 2012, 'Tolerability of HIV integrase inhibitors', Current Opinion in HIV and AIDS, 7, pp. 422 - 428, http://dx.doi.org/10.1097/COH.0b013e328356682a

Carr A; Hoy J; Pozniak A, 2012, 'The ethics of switch/simplify in antiretroviral trials: Non-inferior or just inferior?', PLoS Medicine, 9, http://dx.doi.org/10.1371/journal.pmed.1001240

Bloch MT; Hoy JF; Cummingham N; Roth N; Bailey M; Pearce D; Watson J; Carr AD, 2012, 'Adherence to HIV treatment guidelines for comorbid disease assessment and inititation of antiretroviral therapy', Journal of Acquired Immune Deficiency Syndrome, 59, pp. 478 - 488, http://dx.doi.org/10.1097/QAI.0b013e31824a5473

Botes LP; Pett SL; Carr AD; Marriott D; Cooper DA; Matthews G; Carbone S; Kumaradevan N; Mchugh L; Hillman R, 2012, 'Anal cytological abnormalities are poor predictors of high-grade intraepithelial neoplasia amongst HIV-positive men who have sex with men.', Sexual Health, 10, pp. 9 - 17, http://dx.doi.org/10.1071/SH11135

Haskelberg H; Hoy J; Amin J; Ebeling PR; Emery S; Carr AD, 2012, 'Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine', PLoS ONE, 7, pp. e38377, http://dx.doi.org/10.1371/journal.pone.0038377

Lam UT; Yoganathan R; Carr A; Mammucari R; Foster NR, 2012, 'Encapsulation of superparamagnetic iron oxide nanoparticles by the supercritical antisolvent process', Australian Journal of Chemistry, 65, pp. 40 - 44, http://dx.doi.org/10.1071/CH11360

Koelsch KK, 2012, 'No significant effect of uridine or pravastatin treatment for HIV lip atrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomised trial.', HIV Medicine, 11, pp. 493 - 501

Mcnulty A; Carr A, 2011, 'Approach to those placing others at risk of HIV infection in NSW', Internal Medicine Journal, 41, pp. 365 - 365, http://dx.doi.org/10.1111/j.1445-5994.2011.02462.x

Haskelberg H; Hoy J; Amin J; Ebeling PR; Emery S; Carr A, 2011, 'Lower fat mass and lower bone formation predict greater bone loss with tenofovir in HIV-infected adults', ANTIVIRAL THERAPY, 16, pp. A6 - A7, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375900007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hoy J; Grund B; Roediger MP; Brar I; Colebunders R; De Castro N; Johnson M; Sharma A; Carr A, 2011, 'Plasma markers of bone loss and bone formation decrease with intermittent antiretroviral therapy and predict change in bone mineral density', ANTIVIRAL THERAPY, 16, pp. A5 - A6, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375900006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carr AG; Mammucari R; Foster NR, 2011, 'A review of subcritical water as a solvent and its utilisation for the processing of hydrophobic organic compounds', Chemical Engineering Journal, 172, pp. 1 - 17, http://dx.doi.org/10.1016/j.cej.2011.06.007

McNulty A; Carr AD, 2011, 'Approach to those placing others at risk of HIV infection in NSW', Internal Medicine Journal, 41, pp. 365 - 365, http://dx.doi.org/10.1111/j.1445-5994.2011.02462.x/pdf

Haskelberg H; Carr AD; Emery S, 2011, 'Bone turnover markers in HIV disease', AIDS Reviews, 13, pp. 240 - 250, http://www.aidsreviews.com/files/2011_13_4_240-250.pdf

Wright ST; Carr AD; Woolley I; Giles M; Hoy JF; Cooper DA; Law MG, 2011, 'CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts', Journal of acquired immune deficiency syndromes (1999), 58, pp. 72 - 79, http://dx.doi.org/10.1097/QAI.0b013e318225ba62

Carr AD, 2011, 'eGFR Slope and Tenofovir Nephrotoxicity', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 56, pp. 95 - 96

Hillman R; Pett SL; Marriott D; Carr AD; Cooper DA; Matthews GV; Brew BJ; Milliken S; Botes LP, 2011, 'Participants' perspectives of high resolution anoscopy', Sexual Health, 8, pp. 255 - 256, http://search.informit.com.au/documentSummary;dn=026919938891985;res=IELHEA

Botes LP; Jin F; Bourne CP; Pett SL; Marriott D; Carr AD; Cooper DA; Matthews G; Brew BJ; Hillman R, 2011, 'Participants' perspectives of self-collected anal cytological swabs', Sexual Health, 8, pp. 257 - 258, http://search.informit.com.au/documentSummary;dn=026957204834502;res=IELHEA

Martin A; Amin J; Emery S; Baker D; Carr AD; Cooper DA; Bloch M, 2011, 'Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or Abacavir-Lamivudine', PLoS One, 6, pp. Article number e26885, http://dx.doi.org/10.1371/journal.pone.0026885

Wand HC; Carey DL; Calmy A; Law MG; Cooper DA; Emery S; Carr AD, 2011, 'Prospective evidence that HIV lipoatrophy and visceral adiposity are partially independent processes', Open Access Journal of Clinical Trials, 3, pp. 1 - 7, http://dx.doi.org/10.2147/OAJCT.S14359

Arenas-pinto A; Grant A; Bhaskarin K; Copas A; Carr AD; Worm SW; Martinez E; Reiss P; Dunn ; Weber R; Hoy JF; Weller IV, 2011, 'Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis', Antiviral Therapy, 16, pp. 219 - 226, http://www.intmedpress.com/journals/addToBasket.cfm?id=1739&sPageURL=%2Fjournals%2Favt%2Farticle.cfm%3Fid%3D1739%26pid%3D88%26sType%3DAVT

O''connor MB; O Connor C; Horgan M; Carr AD; Cooper DA, 2011, 'Sexual activity of HIV patients', Irish Journal of Medical Science, 180, pp. 777 - 779, http://www.springerlink.com/content/h371457w3663647x/

Carr AD, 2011, 'Statins as Anti-inflammatory Therapy in HIV Disease?', Journal of Infectious Diseases, 203, pp. 751 - 752, http://jid.oxfordjournals.org/content/203/6/751

Carr A; Hoy J, 2010, 'Low bone mineral density with tenofovir: Does statistically significant mean clinically significant?', Clinical Infectious Diseases, 51, pp. 973 - 975, http://dx.doi.org/10.1086/656418

Carr AG; Mammucari R; Foster NR, 2010, 'Solubility, solubility modeling, and precipitation of naproxen from subcritical water solutions', Industrial and Engineering Chemistry Research, 49, pp. 9385 - 9393, http://dx.doi.org/10.1021/ie9019825

Wever K; Van Agtmael MA; Carr A, 2010, 'Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men', Journal of Acquired Immune Deficiency Syndromes, 55, pp. 78 - 81, http://dx.doi.org/10.1097/QAI.0b013e3181d05579

Molano M; Tabrizi SN; Garland SM; Roberts JM; MacHalek DA; Phillips S; Chandler D; Hillman RJ; Grulich AE; Jin F; Poynten IM; Templeton DJ; Cornall AM; McCaffery K; Howard K; Farnsworth A; Fairley K; Prestage G; Carr A; Tong W; Law C; Acraman B; Crampton L; Feeney L; Fraissard E; Law M; McGrath P; Mellor R; Norris R; O'Dwyer M; Pendlebury S; Petoumenos K; Richards A; Schema L; Seeds D; Segelov E; Thurloe J; Varma R; Han A, 2010, 'CpG methylation analysis of hpv16 in laser capture microdissected archival tissue and whole tissue sections from high grade anal squamous intraepithelial lesions: A potential disease biomarker', PLoS ONE, 11, pp. e0160673, http://dx.doi.org/10.1371/journal.pone.0160673

Calmy A; Fux CA; Delhumeau C; Carr A, 2010, 'Correspondence : Reply to Gazzola et al', Journal of Infectious Diseases, 202, pp. 331 - 332, http://dx.doi.org/10.1086/653585

Amin J; Martin A; Bloch M; Carr A, 2010, 'Reply to Landman and Soonawala', Clinical Infectious Diseases, 50, pp. 1200 - 1201, http://dx.doi.org/10.1086/651469

Martin A; Amin J; Cooper DA; Carr AD; Kelleher AD; Bloch M; Baker D; Woolley I; Emery S, 2010, 'Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial', AIDS, 24, pp. 2657 - 2663

Bloch M; Hoy J; Cunningham N; Roth N; Andrianopoulos N; Rayner C; Carr A, 2010, 'Adherence to HIV treatment guidelines for initiation of antiretroviral therapy in Australia', Journal of the International AIDS Society, 13, http://dx.doi.org/10.1186/1758-2652-13-s4-p172

Yan C; Hanafi I; Kelleher AD; Carr AD; Amin J; Mcnally L; Cunningham PH, 2010, 'Lack of correlation between three commerical platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification', Journal of Clinical Virology, 49, pp. 249 - 253

Sinn K; Richardson R; Carr AD, 2010, 'Lower arterial stiffness and framingham score after switching abacavir to tenofovir in men at high cardiovascular risk', AIDS, 24, pp. 2403 - 2405

Carr A; Mammucari R; Foster NR, 2010, 'Particle formation of budesonide from alcohol-modified subcritical water solutions', International Journal of Pharmaceutics, 405, pp. 169 - 180, http://dx.doi.org/10.1016/j.ijpharm.2010.11.042

Samaras K; Richardson R; Carr AD, 2010, 'Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults', AIDS, 24, pp. 1727 - 1731

Carr A; Mammucari R; Foster NR, 2010, 'Solubility and Micronization of Griseofulvin in Subcritical Water', Industrial and Engineering Chemistry Research, 49, pp. 3403 - 3410, http://dx.doi.org/10.1021/ie901189r

Carr A; Branch A; Mammucari R; Foster NR, 2010, 'The solubility and solubility modelling of budesonide in pure and modified subcritical water solutions', Journal of Supercritical Fluids, 55, pp. 37 - 42, http://dx.doi.org/10.1016/j.supflu.2010.08.001

O'Connor MB; O'Connor C; Saunders JA; Sheehan C; Murphy E; Horgan M; Carr A; Cooper DA, 2009, 'HIV positive: Who do they tell?', International Journal of STD and AIDS, 20, pp. 517 - 518, http://dx.doi.org/10.1258/ijsa.2009.009146

Calmy A; Gayet-Ageron A; Montecucco F; Nguyen A; Mach F; Burger F; Ubolyam S; Carr A; Ruxungtham K; Hirschel B; Ananworanich J, 2009, 'HIV increases markers of cardiovascular risk: Results from a randomized, treatment interruption trial', AIDS, 23, pp. 929 - 939, http://dx.doi.org/10.1097/QAD.0b013e32832995fa

Calmy A; Hirschel B; Cooper DA; Carr AD, 2009, 'A new era of antiretroviral drug toxicity', Antiviral Therapy, 14, pp. 165 - 179

Grund B; Peng G; Gibert C; Hoy JF; Isaksson R; Shlay J; Martinez E; Reiss P; Visnegarwala F; Carr AD, 2009, 'Continuous antiretroviral therapy decreases bone mineral density', AIDS, 23, pp. 1519 - 1529

Samaras K; Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2009, 'Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism', Current HIV Research, 7, pp. 454 - 461

Carr AD; Amin J, 2009, 'Efficacy and tolerability of initial antiretroviral therapy: A systematic review', AIDS, 23, pp. 343 - 353

Calmy A; Fux C; Norris R; Vallier N; Delhumeau C; Samaras K; Hesse K; Hirschel B; Cooper DA; Carr AD; Hesse , 2009, 'Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study', Journal of Infectious Diseases, 200, pp. 1746 - 1754, http://dx.doi.org/10.1086/644785

Mitsuyasu RT; Merigan T; Carr AD; Zack J; Winters M; Workman C; Bloch MT; Lalezari J; Becker S; Thornton L; Akil B; Khanlou H; Finlayson R; Mcfarlane R; Smith DE; Garsia R; Ma DD; Law MG; Murray JM; Von Kalle C; Ely JA; Patino S; Knop A; Wong P; Todd A; Haughton M; Fuery C; Marcpherson J; Symonds G; Evans L; Pond SM; Cooper DA; Cooper D; Han A, 2009, 'Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells', Nature Medicine, 15, pp. 285 - 292, http://dx.doi.org/10.1038/nm.1932

Carey DL; Baker D; Petoumenos K; Chuah J; Rogers G; Watson J; Cooper DA; Emery S; Carr AD, 2009, 'Poly-L-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up', HIV Medicine, 10, pp. 163 - 172

Samaras K; Gan SK; Peake PW; Carr AD; Campbell LV, 2009, 'Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection', Obesity, 17, pp. 53 - 59

Martin A; Bloch MT; Amin J; Baker DL; Cooper DA; Emery S; Carr AD, 2009, 'Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial', Clinical Infectious Diseases, 49, pp. 1591 - 1601

Back to profile page